Hosted on MSN1mon
AdvanCell raises $112m as radiopharma buzz continuesAdvanCell, an Australia-based radiopharmaceutical company, has raised $112m as investor interest in the radiopharma sector continues in 2025. The funding round was co-led by SV Health Investors ...
SYDNEY--(BUSINESS WIRE)-- AdvanCell, a clinical-stage radiopharmaceutical company developing innovative cancer therapeutics, today announced the successful completion of an oversubscribed US$112 ...
AdvanCell, a clinical-stage radiopharmaceutical company specializing in targeted alpha therapies, today announced an expansion to the scope and breadth of its strategic collaboration with Eli ...
On February 10, the company announced a collaboration with AdvanCell to advance cancer treatment through targeted alpha therapies. By combining Eli Lilly and Company’s (NYSE:LLY) expertise in ...
BRISBANE, Australia & INDIANAPOLIS, February 10, 2025--(BUSINESS WIRE)--AdvanCell, a clinical-stage radiopharmaceutical company specializing in targeted alpha therapies, today announced an ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results